James C. Hart - Jul 14, 2023 Form 4 Insider Report for ALPHA HEALTHCARE ACQUISITION CORP III (CTCX)

Role
Chief Medical Officer
Signature
/s/ Randolph W. Hubbell, Attorney-in-Fact
Stock symbol
CTCX
Transactions as of
Jul 14, 2023
Transactions value $
$0
Form type
4
Date filed
7/18/2023, 08:35 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTCX Common Stock Award +37.3K 37.3K Jul 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTCX Stock Option (right to buy) Award +2.08K 2.08K Jul 14, 2023 Common Stock 2.08K $1.79 Direct F2, F8
transaction CTCX Stock Option (right to buy) Award +5.32K 5.32K Jul 14, 2023 Common Stock 5.32K $2.27 Direct F3, F8
transaction CTCX Stock Option (right to buy) Award +9.16K 9.16K Jul 14, 2023 Common Stock 9.16K $2.27 Direct F4, F8
transaction CTCX Stock Option (right to buy) Award +110K 110K Jul 14, 2023 Common Stock 110K $2.11 Direct F5, F8
transaction CTCX Stock Option (right to buy) Award +12.3K 12.3K Jul 14, 2023 Common Stock 12.3K $2.11 Direct F6, F8
transaction CTCX Stock Option (right to buy) Award +12.3K 12.3K Jul 14, 2023 Common Stock 12.3K $2.60 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation.
F2 Options are fully vested and exercisable.
F3 Options to purchase 5,318 shares of common stock of Legacy Carmell granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% will vest on July 19, 2023.
F4 Options to purchase 9,161 shares of common stock of Legacy Carmell granted on July 17, 2020, which vest as follows: 25% vested on July 17, 2021, July 17, 2022 and July 17, 2023 and the remaining 25% becomes vested in 12 equal monthly installments thereafter, subject to continued service through each vesting date.
F5 Options to purchase 109,937 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F6 Options to purchase 12,309 shares of common stock of Legacy Carmell granted on July 13, 2022, which vest as follows: 25% vested on July 13, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F7 Options to purchase 12,309 shares of common stock of Legacy Carmell granted on December 15, 2022, which vest as follows: 25% vested on December 15, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F8 As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.